Independent reference. Not affiliated with, endorsed by, or speaking for the U.S. Food and Drug Administration.

← All approvals · Cancer · 2024

Unloxcyt (cosibelimab-ipdl)

The FDA approved Unloxcyt (cosibelimab-ipdl) on December 13, 2024 to treat cutaneous squamous cell carcinoma.

Brand name: Unloxcyt
Generic name: cosibelimab-ipdl
FDA approval date: December 13, 2024
Approved use (FDA wording): To treat cutaneous squamous cell carcinoma
Category on this site: Cancer

Official sources

FDA novel drug approvals list
FDA announcement

Facts only. This site lists what the FDA has approved and what the FDA says each drug is approved for, quoted or closely paraphrased from FDA and openFDA records. It gives no medical advice, no dosing, and no comparisons, and it says nothing about whether a drug is right for anyone. Talk to a licensed clinician about any medication. Records can lag or contain errors; the FDA's own pages are authoritative.